高效液相色谱法同时测定阿达帕林凝胶剂中的主药阿达帕林和两种防腐剂

20089September2008ChineseJournalofChromatographyVol.26No.5640642:2008203223:,,.E2mail:[e-mail].:,,.Tel:[phone],E2mail:[e-mail].1,2,2,2,1(1.,110016;2.,116021):()(HPLC)TigerkinC18(150mm416mm,5m),pH3100102mol/L22,270nm:,10100mg/L(r=019999);,440mg/L(r=019999);,440mg/L(r=019999)39810%9816%,:;;;;:O658:A:100028713(2008)0520640203:Simultaneousdeterminationofadapalene,22phenoxyethanolandmethyl242hydroxybenzoateinadapalenegelsusinghighperformanceliquidchromatographyZHANGChunhong1,2,ZHAOYingchun2,HANChunhui2,GUOXingjie1(1.SchoolofPharmacy,ShenyangPharmaceuticalUniversity,Shenyang110016,China;2.DalianInstituteforDrugControl,Dalian116021,China)Abstract:Areversed2phasehighperformanceliquidchromatographic(RP2HPLC)methodwasdevelopedforthesimultaneousdeterminationofthecontentsofadapaleneandthepreserva2tives(22phenoxyethanolandmethyl242hydroxybenzoate)inadapalenegels.Thechromato2graphicanalysiswascarriedoutonaTigerkinC18column(150mm416mm,5m).Themo2bilephasewas0102mol/Lammoniumacetatebuffer(pH310)andtetrahydrofuran2acetonitrilewithgradientelution,andthedetectionwavelengthwassetat270nm.Thecalibrationcurveswerelinearovertherangesof10-100mg/L(r=019999),4-40mg/L(r=019999)and4-40mg/L(r=019999)for22phenoxyethanol,methyl242hydroxybenzoateandadapalene,re2spectively.Theaveragerecoveriesofthethreesubstanceswerewithin9810%-9816%.Themethodissimple,reliableandsuitableforthesimultaneousdeterminationofadapalene,22phe2noxyethanolandmethyl242hydroxybenzoateinadapalenegels.Keywords:highperformanceliquidchromatography(HPLC);22phenoxyethanol;methyl242hydroxybenzoate;adapalene;adapalenegels,011%,[1,2],A[3,4](0125%)(011%),[5](HPLC),5,:HPLC,,,11.1Alliance,Waters2695,Waters2996,Chromeleon(9919%);(:070408,070415,070420);(,:05102622)(,9919%);(,9919%),,1.2:TigerkinC18(150mm416mm,5m)A:2(1783);B:0102mol/L(pH310);:0v8min,80%Bv72%B;8v12min,72%Bv5%B;12v25min,5%B;25v30min,5%Bv80%B:270nm;:110mL/min;:20L1.3:25mg10mg,100mL,22(30664),:10mg,100mL,,:510mL,25mL,20102mol/L(pH310)(7525),1.42g,,,10mL,10min,20102mol/L(pH310)(7525)100mL,,,1.52005A[6],22.12.1.1,,32.1.2,,2.1.3270nm,270nm2.22.2.11,215,5,71510mL,5mL,20102mol/L(pH310)(7525),,20L,,(A)(C,mg/L),:A=01192C+01033(r=019999);A=11172C-01049(r=019999);A=11327C+01070(r=019999):10100mg/L,440mg/L,440mg/L(S/N=3)315,016015ng;(S/N=10)1118,210117ng2.2.2,6,(RSD)019%,018%,018%2.2.36,1.4,(,)012385%,RSD111%;010995%,RSD018%;011032%,RSD112%146262.2.40,2,4,8,12,24h,20L,6RSD:019%,110%,114%24h2.2.580%,100%,120%,1.43,20LRSD11(n=3)/g/%RSD/%4.0098.70.45.0097.90.86.0099.42.31.60100.60.32.0099.00.52.4098.81.71.60101.61.12.00100.00.42.40101.01.32.2.6,20L,6000/m12.320L,,422()(n=4)%RSDRSDRSD0704080.23751.10.09910.60.10321.20704150.25010.60.09951.20.10141.00704200.26101.00.10431.40.09781.0051026220.24211.50.10651.00.09951.51a.;b.;c..1.;2.;3..:[1]CunliffeWJ,CaputoR,DrenoB,etal.JAmAcadDerma2tol,1997,36:S126[2]CunliffeWJ,CaputoR,DrenoB,etal.JDermatolTreat,1997,8:173[3],.,1999,28(2):132[4].,1999,8(10):702[5],,,.,2006,26(3):409[6]..2005.,A.:,2005246